Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.

@article{Hasselbalch2003ImatinibMI,
  title={Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.},
  author={Hans Carl Hasselbalch and Ole Weiss Bjerrum and Bjarne Anker Jensen and Nielsaage T\offner Clausen and Per Boye Hansen and Henrik Sverre Birgens and Marianne Hamilton Therkildsen and Elisabeth Methner Ralfkiaer},
  journal={American journal of hematology},
  year={2003},
  volume={74 4},
  pages={238-42}
}
Imatinib mesylate targets the adenosine triphosphate (ATP)-binding sites of the protein tyrosine kinase domains associated with Bcr-abl, the platelet-derived growth factor (PDGF) and c-kit. In idiopathic myelofibrosis (IMF) PDGF is considered to be one of the growth factors responsible for the development of bone marrow fibrosis. Recently, it has been shown that imatinib has antifibrogenic effect on bone marrow fibrosis in chronic myelogenous leukemia. Treatment with imatinib alone in IMF has… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Similar Papers

Loading similar papers…